Director/PDMR Shareholding

EpiStem Holdings plc
23 October 2007


                    EXECUTIVE DIRECTOR AWARDED SHARE OPTIONS


Manchester, UK, 23rd October 2007 - Epistem Holdings Plc (AIM: EHP) announced
today that Dr Gerard Brady, Research Director, has been awarded share options as
detailed below. The share options will vest according to the performance and
delivery of the Company's robotic Biomarker technology platform.  For the share
options to fully vest at the end of the three year period would require
Epistem's Biomarker technology to be established by the third year of grant.


The share options have an exercise price of 160 pence, being the closing share
price on 15th October 2007.


Following this award, Dr Brady will hold the following numbers of share options:


Executive              Share option  New share options Total share option Share options held as
Director           holding prior to            granted      holding after   % of issued capital
                              award                                 award


Dr Gerard Brady             132,877             57,725            190,602                 2.92%


In July 2007, just following the Company's admission to AIM, Dr Gerard Brady
also received 12,653 options under the Enterprise Management Incentive (EMI)
scheme at an exercise price of 167p for his performance and contribution in
progressing the Company's Novel Therapeutic development program.


For further information, please contact:


Matthew Walls

CEO

Epistem Holdings Plc                              0161 606 7258


Thilo Hoffmann

Landsbanki Securities UK                          0207 426 9000


Mike Wort, Anna Dunphy

MC Bio-Communications                             0207 744 7711


                                    - ENDS -


                      This information is provided by RNS
            The company news service from the London Stock Exchange